227 related articles for article (PubMed ID: 34417459)
1. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Mao N; Zhang Z; Lee YS; Choi D; Rivera AA; Li D; Lee C; Haywood S; Chen X; Chang Q; Xu G; Chen HA; de Stanchina E; Sawyers C; Rosen N; Hsieh AC; Chen Y; Carver BS
Nat Commun; 2021 Aug; 12(1):5053. PubMed ID: 34417459
[TBL] [Abstract][Full Text] [Related]
2. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
3. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
4. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
5. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
6. Should individual PI3 kinase isoforms be targeted in cancer?
Jia S; Roberts TM; Zhao JJ
Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
[TBL] [Abstract][Full Text] [Related]
7. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
9. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ
Nature; 2008 Aug; 454(7205):776-9. PubMed ID: 18594509
[TBL] [Abstract][Full Text] [Related]
10. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.
Kaysudu I; Gungul TB; Atici S; Yilmaz S; Bayram E; Guven G; Cizmecioglu NT; Sahin O; Yesiloz G; Haznedaroglu BZ; Cizmecioglu O
Cancer Sci; 2023 Nov; 114(11):4365-4375. PubMed ID: 37706278
[TBL] [Abstract][Full Text] [Related]
13. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
14. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
15. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
16. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Xie S; Ni J; McFaline-Figueroa JR; Wang Y; Bronson RT; Ligon KL; Wen PY; Roberts TM; Zhao JJ
Cell Rep; 2020 Sep; 32(13):108196. PubMed ID: 32997991
[TBL] [Abstract][Full Text] [Related]
17. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
18. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
[TBL] [Abstract][Full Text] [Related]
20. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
